GLOBAL BIOENERGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.788 EUR | +2.17% |
|
-2.83% | -11.49% |
| 04-09 | Global Bioenergies Receives EUR70 Million Indicative Orders for New Plant | MT |
| 03-06 | Global Bioenergies SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 31.16 | 32.4 | 69.71 | 56.18 | 44.41 | 32.35 | 32.35 | - |
| Enterprise Value (EV) 1 | 29.76 | 25.17 | 68.03 | 42.45 | 46.96 | 36.55 | 37.7 | 39.55 |
| P/E ratio | -2.29 x | -2.55 x | -6.98 x | -6.27 x | -3.74 x | -3.06 x | -2.84 x | -3.11 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.9 x | 9.27 x | 21.3 x | 14.5 x | 25.9 x | 4.1 x | 18.5 x | 15.8 x |
| EV / Revenue | 12.3 x | 7.2 x | 20.8 x | 10.9 x | 27.4 x | 4.1 x | 21.5 x | 19.3 x |
| EV / EBITDA | -2.47 x | -2.39 x | -6.96 x | -3.83 x | -4.13 x | -5.31 x | -4.28 x | -4.39 x |
| EV / FCF | -3.55 x | -2.39 x | -6.03 x | -2.88 x | -3.88 x | -4.56 x | -3.61 x | -2.59 x |
| FCF Yield | -28.2% | -41.8% | -16.6% | -34.7% | -25.8% | -21.9% | -27.7% | -38.6% |
| Price to Book | 4.97 x | 3.34 x | 18.8 x | - | - | -9.93 x | -3.51 x | -1.5 x |
| Nbr of stocks (in thousands) | 5,075 | 8,709 | 9,077 | 11,349 | 14,854 | 18,092 | 18,092 | - |
| Reference price 2 | 6.140 | 3.720 | 7.680 | 4.950 | 2.990 | 1.788 | 1.788 | 1.788 |
| Announcement Date | 01/03/19 | 11/03/20 | 15/03/21 | 02/03/22 | 14/02/23 | 06/03/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.412 | 3.494 | 3.276 | 3.881 | 1.715 | 8.91 | 1.75 | 2.05 |
| EBITDA 1 | -12.06 | -10.53 | -9.777 | -11.09 | -11.37 | -6.878 | -8.8 | -9 |
| EBIT 1 | -15.68 | -14.02 | -13.06 | -13.35 | -13.19 | -9.711 | -11.45 | -11.8 |
| Operating Margin | -649.92% | -401.37% | -398.53% | -343.93% | -769.21% | -108.99% | -654.29% | -575.61% |
| Earnings before Tax (EBT) | -16.18 | - | -13.41 | - | - | - | - | - |
| Net income 1 | -13.64 | -12.74 | -11.15 | -11.77 | -11.99 | -8.656 | -8.7 | -9.5 |
| Net margin | -565.38% | -364.65% | -340.29% | -303.35% | -698.89% | -97.15% | -497.14% | -463.41% |
| EPS 2 | -2.680 | -1.460 | -1.100 | -0.7900 | -0.8000 | -0.5850 | -0.6300 | -0.5750 |
| Free Cash Flow 1 | -8.392 | -10.51 | -11.29 | -14.72 | -12.1 | -6.7 | -10.45 | -15.25 |
| FCF margin | -347.93% | -300.83% | -344.62% | -379.33% | -705.61% | -135.35% | -597.14% | -743.9% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 01/03/19 | 11/03/20 | 15/03/21 | 02/03/22 | 14/02/23 | 06/03/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 2.55 | - | 5.35 | 7.2 |
| Net Cash position 1 | 1.4 | 7.23 | 1.68 | 13.7 | - | 1.8 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.2239 x | - | -0.608 x | -0.8 x |
| Free Cash Flow 1 | -8.39 | -10.5 | -11.3 | -14.7 | -12.1 | -6.7 | -10.5 | -15.3 |
| ROE (net income / shareholders' equity) | -136% | -159% | -161% | -94.1% | -44.9% | - | 147% | 2,656% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | 1,464% | - |
| Assets 1 | - | - | - | - | - | - | -0.5941 | - |
| Book Value Per Share 2 | 1.240 | 1.110 | 0.4100 | - | - | -0.1800 | -0.5100 | -1.190 |
| Cash Flow per Share 2 | -1.460 | -1.180 | -1.050 | -0.8000 | -0.6800 | -0.5500 | -0.6200 | -0.6400 |
| Capex 1 | 0.97 | 0.24 | 0.61 | 2.85 | 1.95 | 1 | 1.5 | 10 |
| Capex / Sales | 40.38% | 6.9% | 18.54% | 73.33% | 113.8% | 20.2% | 85.71% | 487.8% |
| Announcement Date | 01/03/19 | 11/03/20 | 15/03/21 | 02/03/22 | 14/02/23 | 06/03/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.788
EUR
Average target price
2.6
EUR
Spread / Average Target
+45.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.49% | 34.53M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- ALGBE Stock
- Financials Global Bioenergies
